Trial Information

1. To survey the incidence of HPV infection in CIN and cervical cancer patients.

Using epidemiologic data drawn from a wide range of countries and population groups,
investigators have found evidence of HPV in 90% to 95% of cervical cancers. The
incidence of HPV in cervical cancer was 79% in our own report. Besides, 91% of
high-grade CIN cases and 50% of low-grade CIN cases could be attributed to HPV
infection in Taiwanese women. Because these reports for Taiwanese women were published
around 10 years ago, it is important to survey and update the incidence of HPV in CIN
and cervical cancer patients in Taiwanese women. We will survey the incidence of HPV
infection in 500 cervical cancer patients, 100 patients of CIN and 100 normal
population patients.

2. To survey the human leukocyte antigen haplotype in CIN and cervical cancer patients.

HLA class I and II alleles have been reported to associate with the nasopharyngeal
carcinoma in Taiwan. Besides, human leukocyte antigen class I and II alleles might
interplay in the response to interferon-alpha treatment in Taiwanese patients with
chronic hepatitis C virus infection. We will detect the HLA class I and II haplotype
first and then correlate them with the CIN and cervical cancer patients.

3. To identify the correlation between HLA class I and II haplotype and HPV infection and
CIN and cervical cancer.

We will further survey the correlation between HLA class I and II and the genotypes of
HPV in CIN and cervical cancer patients. We will identify which HLA class I and II
haplotypes have positive or negative correlation with HPV infection, CIN and cervical
cancer. Then we would determine which specific HLA antigens are important in
determining the risk of HPV infection, CIN and cervical cancer.

4. To elucidate the immunologic responses to HPV type 16 in HLA2 with different II
haplotypes and the role of immunogenetics in the carcinogenesis of cervical cancer.

HPV type 16 has been identified to be the highest incidence of malignant HPV genotypes in
cervical cancer. Our laboratory has set up immunologic assays for evaluating the immune
responses to HPV type 16. We will survey the immune response to HPV type 16 in those HLA
class I and II haplotypes which have positive or negative correlation with the HPV infection
and cervical cancer. We would identify which population of HLA genotype are more susceptible
to HPV infection and invasive cervical cancer and elucidate the role of immunogenetics in
the HPV infection and carcinogenesis of cervical cancer.